Article citationsMore >>

Birnie, D.H., et al., HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm, 2014. 11(7): p. 1305-23.

has been cited by the following article:

Article

Extrapulmonary Involvement in Sarcoidosis: A Case Report

1Department of Internal Medicine, State University of New York- Downstate Health Science University, Brooklyn, NY, USA- 11203


American Journal of Medical Case Reports. 2020, Vol. 8 No. 7, 210-215
DOI: 10.12691/ajmcr-8-7-13
Copyright © 2020 Science and Education Publishing

Cite this paper:
Courtney Connelly, Abida Hasan, Zachary Chung, Erli Mingomataj, Vinodkumar Velayudhan, Isabel M. McFarlane. Extrapulmonary Involvement in Sarcoidosis: A Case Report. American Journal of Medical Case Reports. 2020; 8(7):210-215. doi: 10.12691/ajmcr-8-7-13.

Correspondence to: Isabel  M. McFarlane, Department of Internal Medicine, State University of New York- Downstate Health Science University, Brooklyn, NY, USA- 11203. Email: Isabel.McFarlane@downstate.edu

Abstract

Sarcoidosis is an idiopathic multisystem granulomatous disease that affects patients of all races and ethnic groups however predilection for women and African Americans is apparent. Extrapulmonary manifestations of sarcoidosis occur in up to 50% of cases. The most common sites of extrapulmonary involvement are the skin, eyes, liver, and reticuloendothelial system followed bt renal, cardiac, and neurological involvement. We present the case of a middle age man with exclusive extrapulmonary sarcoidosis affecting the renal, cardiac, hepatic, splenic and central nervous system. The patient sustained a second episode of venous thromboembolism which highlights a frequently seen complication of sarcoidosis. We discuss the proposed pathophysiology for the prothrombotic state seen in sarcoidosis and imaging modalities that can be utilized to assess extrapulmonary involvement in sarcoidosis. Lastly, sarcoidosis management is reviewed, highlighting that immunosuppressants and tumor necrosis factor inhibitors are being proposed to arrest disease progression and reduce glucocorticoid doses.

Keywords